Your treatment for prostate cancer will depend on your individual circumstances.
For most men with low risk prostate cancer, no treatment will be necessary. Active surveillance will mean keeping an eye on the cancer and starting treatment only if the cancer shows signs of getting worse or causes symptoms.
When treatment is necessary, the aim is to cure or control the disease, so it doesn't shorten life expectancy and affect everyday life as little as possible. Sometimes, if the cancer has already spread, the aim is not to cure it, but to prolong life and delay the onset of symptoms.
One or more of the following treatments may be an option for you.
Active surveillance aims to avoid unnecessary treatment of harmless cancers, while still providing timely treatment for men who need it. When they are diagnosed, we know that around half to two-thirds of men with low-risk prostate cancer do not need treatment. Surveillance is a safe strategy that provides a period of observation to gather extra information over time to see whether the disease is changing.
Active surveillance involves you having regular PSA tests and imaging scans to ensure any signs of progression are found as early as possible. If these tests reveal the cancer is changing or progressing, you can then make a decision about further treatment.
About one in three men who undergo surveillance will later have treatment. This does not mean they made the wrong initial decision. Good evidence shows that active surveillance is safe for men with low risk prostate cancer. Men undergoing active surveillance will have delayed any treatment-related side effects, and those who eventually need treatment will be reassured that it was necessary.
A radical prostatectomy is the surgical removal of your prostate gland, and is typically undertaken using the robotic technique. This treatment is an option to attempt to cure localised and locally-advanced prostate cancer. It is offered to men with more aggressive disease.
UCLH performs the most number of radical prostatectomies to remove the prostate gland in the UK. The robotic system is the most up-to-date technology, where a surgeon controls key-hole surgery (laparoscopic) instruments to undertake the procedure while seated in the operating room beside the patient.
Robotic surgery is used to remove the prostate, seminal vesicles (tube-like glands which make semen) and occasionally lymph nodes. The da Vinci system provides the surgeon with controlled and precise movements mimicking the human hand and wrist. The surgeon is in full control of the system at all times and can operate in highly magnified 3D.
Robotic prostatectomy is performed under general anaesthetic. It involves the use of a number of “ports” (hollow tubes). The robotic instruments pass into the body via these tubes to access and operate on the diseased organ.
As the robotic surgery is performed laparoscopically (key-hole surgery), we have found that patients benefit from a reduced recovery time, reduced pain following the procedure and from far less visible scarring.
Radiotherapy involves using radiation to kill cancerous cells. This treatment is an option to attempt to cure localised and locally advanced prostate cancer. Radiotherapy can also be used to slow the progression of metastatic prostate cancer and relieve symptoms.
You may receive hormone therapy before undergoing radiotherapy to increase the chance of successful treatment. Hormone therapy may also be recommended after radiotherapy to reduce the chances of cancerous cells returning.
It is possible to have surgical treatment of prostate cancer if it recurs, but this can be technically very challenging in men who have previously had radiotherapy.
UCLH is the largest national centre for providing High Intensity Focussed Ultrasound (HIFU) treatment for prostate cancer. This is a targeted therapy for prostate cancer which uses high frequency ultrasound waves to destroy cancer cells in the prostate. HIFU is used to treat men with localised prostate cancer that has not spread beyond their prostate.
An ultrasound probe inserted into the rectum releases high-frequency sound waves through the wall of the rectum. These sound waves kill cancer cells in the prostate gland by heating them to a high temperature.
The risk of side effects from HIFU is usually lower than other treatments. However, possible effects can include erectile dysfunction (in five to 10 in every 100 men) or urinary incontinence (in less than one in every 100 men). Back passage problems are rare. Fistulas (an abnormal channel between the urinary system and rectum) are also rare, affecting less than one in every 700 men. This is because the treatment targets the cancer area only and not the whole prostate.
Cryotherapy is a method of killing cancer cells by freezing them. It is sometimes used to treat men with localised prostate cancer that has not spread beyond their prostate gland. Tiny probes called cryoneedles are inserted into the prostate gland through the wall of the rectum. They freeze the prostate gland and kill the cancer cells, but some normal cells also die. The aim is to kill cancer cells while causing as little damage as possible to healthy cells. The side effects of cryotherapy can include erectile dysfunction and incontinence. It is rare for cryotherapy to cause rectal problems or fistulas.
Brachytherapy is a form of radiotherapy where the radiation dose is delivered inside the prostate gland. The radiation can be delivered using a number of tiny radioactive seeds that are surgically implanted into the tumour. This is called low dose-rate brachytherapy.
The radiation can also be delivered through hollow, thin needles placed inside the prostate. This is called high dose-rate brachytherapy. This method has the advantage of delivering a high dose of radiation to the prostate, while minimising damage to other tissues.
However, the risk of sexual dysfunction and urinary problems is the same as with radiotherapy, although the risk of bowel problems is slightly lower.
Hormone therapy is often used in combination with radiotherapy. For example, you may receive hormone therapy before undergoing radiotherapy to increase the chance of a successful treatment. Hormone therapy may also be recommended after radiotherapy to reduce the chances of cancerous cells returning.
Hormone therapy alone should not normally be used to treat localised prostate cancer in men who are fit and willing to receive surgery or radiotherapy. This is because it does not cure the cancer on its own. Hormone therapy can be used to slow the progression of advanced prostate cancer and relieve symptoms.
Hormones control the growth of cells in the prostate. In particular, prostate cancer needs the hormone testosterone to grow. The purpose of hormone therapy is to block the effects of testosterone, either by stopping its production or by stopping your body being able to use testosterone.
Hormone therapy can be given as:
- injections to stop your body making testosterone, called luteinising hormone-releasing hormone (LHRH) agonists
- tablets to block the effects or reduce the production of testosterone, called anti-androgen treatment
- combined LHRH and anti-androgen treatment
The main side effects of hormone treatment are caused by their effects on testosterone. They usually go away when treatment stops. They include loss of sex drive and erectile dysfunction (this is more common with LHRH agonists than anti-androgens).
Watchful waiting is often recommended for older men when it is unlikely that the cancer will affect your natural life span. If the cancer is in its early stages and not causing symptoms, you may decide to delay treatment, and wait to see if any symptoms of progressive cancer develop. If this happens, pain medication and hormone medication (see below) to control prostate cancer are usually used. Watchful waiting may also be recommended for people with a higher risk of prostate cancer if:
- your general health means you are unable to receive any form of treatment
- your life expectancy means you will die with the cancer rather than from it
In this case, hormone treatment may be started if there are symptoms caused by the prostate cancer.
During TURP, a thin metal wire with a loop at the end is inserted into your urethra (the tube that carries urine from your bladder to your penis) and pieces of the prostate are removed. This is carried out under general anaesthetic or a spinal anaesthetic (epidural). This is done to relieve pressure from the urethra to treat any problematic symptoms you may have with urination. It does not cure the cancer.
Advanced prostate cancer, where the cancer has spread to more distant sites such as bone or other organs, is no longer curable but remains very treatable. Treatment of advanced prostate cancer has improved significantly over the last 10 years and there are several possible treatment options for advanced disease.
Hormone treatment
The male sex hormone testosterone is the main driver of advanced prostate cancer. Lowering testosterone levels with hormonal treatment – usually in the form of regular injections – is a very effective way to treat advanced prostate cancer. Often, additional hormone blocking tablets (enzalutamide, abiraterone, apalutamide) are added to these regular injections and these combinations of treatments are known to improve outcome for patients with advanced disease. Your oncology team will discuss which combination is best for you.
Chemotherapy
Chemotherapy works by stopping cancer cells dividing, growing and spreading, so is an effective treatment for many cancers. Two chemotherapy drugs – docetaxel and cabazitaxel – are used in advanced prostate cancer, most usually when hormonal treatment alone is no longer effective. Whilst destroying cancer cells, chemotherapy also has an effect on normal cells and typical side effects can include nausea, fatigue, hair thinning and increased risk of infection. However, most patients tolerate chemotherapy for prostate cancer very well and it can help improve symptoms and quality of life.
Targeted treatment
Radium 223 is a bone targeting treatment and suitable for patients with advanced prostate cancer that has spread only to bone. This is usually given after chemotherapy and hormonal treatment. Radium is similar to calcium and can be absorbed by prostate cancer cells in the bones. Radium 223 is a radioactive form of radium and releases radiation locally in the bone, damaging cancer cells and can be very effective in reducing pain and symptoms caused by disease that has spread to the bones.
Olaparib is a newly available targeted treatment, but only suitable for some patients with advanced prostate cancer. A minority of patients may have a genetic risk for developing prostate cancer and carry a defective gene, called BRCA, which means their cells are not efficient at repairing damage. Overtime, this can increase the risk of developing prostate cancer. Men with advanced prostate cancer, who have been tested for a BRCA mutation and have tested positive, may be offered a tablet treatment called Olaparib, which is a PARP inhibitor. PARPs are proteins that help repair damaged cells. By blocking PARP, cancer cells are more likely to be damaged and die. Olaparib can be given if hormonal treatment or chemotherapy is no longer effective.
Radiotherapy
In advanced prostate cancer, disease that has spread to other sites can start to cause symptoms such as pain, bleeding or pressure. Radiotherapy is a very effective treatment to help relieve symptoms and often only a single dose is needed to improve symptoms and quality of life.
Clinical trials
The UCLH oncology team lead on many clinical trials in advanced prostate cancer. Trials are an opportunity to receive new treatments for prostate cancer and improve outcomes for all patients. Many of the developments in treatment in advanced prostate cancer over the last 10 years have come from clinical trials. If you are suitable or interested in trials, your oncology team will discuss these opportunities with you. It is always your decision if you wish to join a trial or not and does not impact on any other treatment you will be offered.
Chemotherapy is mainly used to treat prostate cancer that has spread to other parts of the body (metastatic prostate cancer) and which is not responding to hormone therapy.
Chemotherapy destroys cancer cells by interfering with the way they multiply. Chemotherapy does not cure prostate cancer, but can keep it under control and reduce symptoms (such as pain) so everyday life is less affected. The main side effects of chemotherapy are caused by their effects on healthy cells, such as immune cells. They include infections, tiredness, hair loss, sore mouth, loss of appetite, nausea and vomiting. Many of these side effects can be prevented or controlled with other medicines, which your doctor can prescribe for you.
Steroid tablets are used when hormone therapy no longer works because the cancer is resistant to it. This is called hormone-refractory cancer. Steroids can be used to try to shrink the tumour and stop it from growing. The most effective steroid treatment is dexamethasone.
